Your browser doesn't support javascript.
loading
Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins.
Pance, Katarina; Gramespacher, Josef A; Byrnes, James R; Salangsang, Fernando; Serrano, Juan-Antonio C; Cotton, Adam D; Steri, Veronica; Wells, James A.
Afiliação
  • Pance K; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
  • Gramespacher JA; EpiBiologics, Inc., San Carlos, CA, USA.
  • Byrnes JR; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
  • Salangsang F; EpiBiologics, Inc., San Carlos, CA, USA.
  • Serrano JC; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
  • Cotton AD; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Steri V; Preclinical Therapeutics Core, University of California San Francisco, San Francisco, CA, USA.
  • Wells JA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Nat Biotechnol ; 41(2): 273-281, 2023 02.
Article em En | MEDLINE | ID: mdl-36138170
ABSTRACT
Targeted degradation of cell surface and extracellular proteins via lysosomal delivery is an important means to modulate extracellular biology. However, these approaches have limitations due to lack of modularity, ease of development, restricted tissue targeting and applicability to both cell surface and extracellular proteins. We describe a lysosomal degradation strategy, termed cytokine receptor-targeting chimeras (KineTACs), that addresses these limitations. KineTACs are fully genetically encoded bispecific antibodies consisting of a cytokine arm, which binds its cognate cytokine receptor, and a target-binding arm for the protein of interest. We show that KineTACs containing the cytokine CXCL12 can use the decoy recycling receptor, CXCR7, to target a variety of target proteins to the lysosome for degradation. Additional KineTACs were designed to harness other CXCR7-targeting cytokines, CXCL11 and vMIPII, and the interleukin-2 (IL-2) receptor-targeting cytokine IL-2. Thus, KineTACs represent a general, modular, selective and simple genetically encoded strategy for inducing lysosomal delivery of extracellular and cell surface targets with broad or tissue-specific distribution.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Citocinas / Quimera de Direcionamento de Proteólise Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Citocinas / Quimera de Direcionamento de Proteólise Idioma: En Ano de publicação: 2023 Tipo de documento: Article